Urgent need for pragmatic trial platforms in severe asthma
(2018) The Lancet Respiratory Medicine — Vol. 6, n° 8, p. 581-583 (2018)
Files
No attached file found for this publication.
Details
- Authors
- et. al.
- Abstract
- (en) Asthma is a highly prevalent chronic disease of the airways affecting people of all ages. Worldwide, asthma causes significant morbidity, disability, and mortality. Most patients' mild-to-moderate asthma can be well controlled with inhaled corticosteroids, either as monotherapy or in combination with a second controller (eg, long-acting β 2-agonists [LABAs]). However, a subgroup of patients with severe asthma remain symptomatic and experience asthma exacerbations despite maintenance treatment with high-dose inhaled corticosteroids or LABAs […]
- Affiliations
Citations
Pilette, C., Brightling, C., Lacombe, D., Brusselle, G., & et al. (2018). Urgent need for pragmatic trial platforms in severe asthma. The Lancet Respiratory Medicine, 6(8), 581-583. https://doi.org/10.1016/S2213-2600(18)30291-1 (Original work published 2018)